Cargando…

Is Endogenous Fibrinolysis a Major Player in Occurrence of Atherothrombotic Events Following Acute Myocardial Infarction?

Detalles Bibliográficos
Autores principales:	Kang, Min Gyu, Byeon, Kyeongmin, Jeong, Young-Hoon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Original Research - Clinical
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9849456/ https://www.ncbi.nlm.nih.gov/pubmed/36687276 http://dx.doi.org/10.1016/j.jacbts.2022.08.008

Ejemplares similares

Determinants of Endogenous Fibrinolysis in Whole Blood Under High Shear in Patients With Myocardial Infarction
por: Kanji, Rahim, et al.
Publicado: (2022)

Atherothrombotic risk stratification after acute myocardial infarction: The Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention in the light of the French Registry of Acute ST Elevation or non‐ST Elevation Myocardial Infarction registries
por: Puymirat, Etienne, et al.
Publicado: (2018)

Apixaban enhances endogenous fibrinolysis in patients with atrial fibrillation
por: Spinthakis, Nikolaos, et al.
Publicado: (2019)

Vasoconstrictor component of atherothrombotic culprit lesions in ST-segment elevation myocardial infarction
por: Her, Ae-Young, et al.
Publicado: (2019)

Antiplatelet combinations for prevention of atherothrombotic events
por: Bollati, Mario, et al.
Publicado: (2011)

Endothelial Progenitor Cells Predict Cardiovascular Events after Atherothrombotic Stroke and Acute Myocardial Infarction. A PROCELL Substudy
por: Cuadrado-Godia, Elisa, et al.
Publicado: (2015)

Ticagrelor for Secondary Prevention of Atherothrombotic Events After Myocardial Infarction: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Pouwels, Xavier G. L. V., et al.
Publicado: (2018)

Case Report: ST-Elevation Myocardial Infarction Secondary to Acute Atherothrombotic Occlusion Treated With No Stent Strategy
por: Dhawan, Rahul, et al.
Publicado: (2022)

Ramipril and Losartan Exert a Similar Long-Term Effect upon Markers of Heart Failure, Endogenous Fibrinolysis, and Platelet Aggregation in Survivors of ST-Elevation Myocardial Infarction: A Single Centre Randomized Trial
por: Marinšek, Martin, et al.
Publicado: (2016)

Importance of Endogenous Fibrinolysis in Platelet Thrombus Formation
por: Gue, Ying X., et al.
Publicado: (2017)

Novel Antiplatelet Therapies for Atherothrombotic Diseases
por: Majithia, Arjun, et al.
Publicado: (2019)

Vorapaxar in Patients With Diabetes Mellitus and Previous Myocardial Infarction: Findings From the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events-TIMI 50 Trial
por: Cavender, Matthew A., et al.
Publicado: (2015)

Synthesis and Preliminary Evaluation of N-Oxide Derivatives for the Prevention of Atherothrombotic Events
por: Rosseto, Leandro Augusto, et al.
Publicado: (2015)

Ways of Coping and Biomarkers of an Increased Atherothrombotic Cardiovascular Disease Risk in Elderly Individuals
por: von Känel, Roland, et al.
Publicado: (2012)

A fibrinolysis-first strategy for ST-elevation myocardial infarction in the COVID-19 era
por: Jamal, Javeria, et al.
Publicado: (2021)

Filgrastim, fibrinolysis, and neovascularization
por: Eton, Darwin, et al.
Publicado: (2022)

The High-Risk Plaque Initiative: Primary Prevention of Atherothrombotic Events in the Asymptomatic Population
por: Falk, Erling, et al.
Publicado: (2011)

α-Hydroxybutyrate dehydrogenase is associated with atherothrombotic events following infrainguinal angioplasty and stenting
por: Lee, Silvia, et al.
Publicado: (2019)

The activity of pregnancy-associated plasma protein A (PAPP-A) as expressed by immunohistochemistry in atherothrombotic plaques obtained by aspiration thrombectomy in patients presenting with a ST-elevation myocardial infarction: a brief communication
por: Brügger-Andersen, Trygve, et al.
Publicado: (2010)

Hematopoiesis of Indeterminate Potential and Atherothrombotic Risk
por: Murphy, Andrew J., et al.
Publicado: (2022)

Unexplored Roles of Erythrocytes in Atherothrombotic Stroke
por: Papadopoulos, Charalampos, et al.
Publicado: (2023)

PCSK9 as an Atherothrombotic Risk Factor
por: Sotler, Tadeja, et al.
Publicado: (2023)

Reply to a fibrinolysis-first strategy for ST-elevation myocardial infarction in the COVID-19 era
por: Leng, Wen-Xiu, et al.
Publicado: (2021)

Effect of ω-3 fatty acid supplementation on endothelial function, endogenous fibrinolysis and platelet activation in patients with a previous myocardial infarction: a randomised controlled trial
por: Din, Jehangir N, et al.
Publicado: (2013)

Cardiovascular Events in Patients with Atherothrombotic Disease: A Population-Based Longitudinal Study in Taiwan
por: Lee, Wen-Hsien, et al.
Publicado: (2014)

Targeting blood thrombogenicity precipitates atherothrombotic events in a mouse model of plaque destabilization
por: Liu, Xiaoling, et al.
Publicado: (2015)

A Case of Brainstem Infarction That Was Found to Be Vertebral Artery Dissection in a Short Period after the Diagnosis of Atherothrombotic Infarction
por: Edaki, Hisanori, et al.
Publicado: (2020)

Fibrinolysis vs. primary percutaneous coronary intervention for ST‐segment elevation myocardial infarction cardiogenic shock
por: Vallabhajosyula, Saraschandra, et al.
Publicado: (2021)

Association Between Thrombogenicity Indices and Coronary Microvascular Dysfunction in Patients With Acute Myocardial Infarction
por: Kang, Min Gyu, et al.
Publicado: (2021)

Environmental noise exposure is associated with atherothrombotic risk
por: Koczorowski, Magali, et al.
Publicado: (2022)

Role of Oxidative Stress in the Pathogenesis of Atherothrombotic Diseases
por: Petrucci, Giovanna, et al.
Publicado: (2022)

Systemic Hemodynamic Atherothrombotic Syndrome and Resonance Hypothesis of Blood Pressure Variability: Triggering Cardiovascular Events
por: Kario, Kazuomi
Publicado: (2016)

Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)‐TIMI 50
por: Kidd, Stephen K., et al.
Publicado: (2016)

Delay of Fibrinolysis in ST- Elevation Myocardial Infarction: Results of an Investigation Conducted in a Single Center in Sousse Tunisia
por: Bouraoui, Hatem, et al.
Publicado: (2014)

Chronic kidney disease and the outcomes of fibrinolysis for ST-segment elevation myocardial infarction: A real-world study
por: Xie, Wuxiang, et al.
Publicado: (2021)

Lack of prognostic significance for major adverse cardiac events of soluble suppression of tumorigenicity 2 levels in patients with ST-segment elevation myocardial infarction
por: Kim, Min, et al.
Publicado: (2021)

Impaired fibrinolysis in critically ill COVID-19 patients
por: Bachler, Mirjam, et al.
Publicado: (2021)

Analysis between high risk of myocardial infarction with non‐obstructive coronary artery disease in single center and occurrence of major adverse cardiovascular events
por: Kong, Meihong, et al.
Publicado: (2022)

The Role of Biomarkers in Atherothrombotic Stroke—A Systematic Review
por: Andone, Sebastian, et al.
Publicado: (2021)

Pharmacogenomics of Cardiovascular Drugs for Atherothrombotic, Thromboembolic and Atherosclerotic Risk
por: Mauriello, Alfredo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1c23nk5e5a70lon1mh47k520l0